Latest news with #GDRX
Yahoo
7 days ago
- Business
- Yahoo
GDRX vs. HQY: Which Stock Is the Better Value Option?
Investors with an interest in Medical Services stocks have likely encountered both GoodRx Holdings, Inc. (GDRX) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits. Currently, GoodRx Holdings, Inc. has a Zacks Rank of #2 (Buy), while HealthEquity has a Zacks Rank of #3 (Hold). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that GDRX has an improving earnings outlook. But this is just one factor that value investors are interested in. Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels. The Value category of the Style Scores system identifies undervalued companies by looking at a number of key metrics. These include the long-favored P/E ratio, P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that help us determine a company's fair value. GDRX currently has a forward P/E ratio of 12.80, while HQY has a forward P/E of 27.57. We also note that GDRX has a PEG ratio of 1.15. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. HQY currently has a PEG ratio of 1.32. Another notable valuation metric for GDRX is its P/B ratio of 2.64. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, HQY has a P/B of 4.2. These metrics, and several others, help GDRX earn a Value grade of B, while HQY has been given a Value grade of D. GDRX stands above HQY thanks to its solid earnings outlook, and based on these valuation figures, we also feel that GDRX is the superior value option right now. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GoodRx Holdings, Inc. (GDRX) : Free Stock Analysis Report HealthEquity, Inc. (HQY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
28-06-2025
- Business
- Yahoo
GoodRx (GDRX) Unveils Lifecycle to Enhance Engineering Methodologies
GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the 10 best-value penny stocks to buy, according to analysts. On June 6, the company launched Lifecycle, a development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. The tool enables engineering, quality control, and platform teams to automatically create temporary, isolated environments for testing and assessing code modifications under actual conditions. Lifecycle has also helped GoodRx minimize deployment challenges, enhance teamwork across different functions during code assessments, and decrease expenses related to prolonged staging infrastructure. The new tool underscores GoodRx's commitment to contemporary engineering methodologies and transparent collaboration. Lifecycle has been released to the public under the Apache 2.0 license, encouraging developers and organizations to adopt, enhance, and contribute to the platform's growth. 'Open sourcing Lifecycle reflects our commitment to transparency and to empowering developers. It's not just about sharing code, it's about sharing the ideas and practices that can help teams everywhere move faster and work smarter,' said Nitin Shingate, Chief Technology Officer at GoodRx. GoodRx Holdings, Inc. (NASDAQ:GDRX) is a digital healthcare platform that helps people find affordable prescription medications and other healthcare services. It primarily works by comparing drug prices at different pharmacies, offering discounts, and providing access to telemedicine services. While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-06-2025
- Business
- Yahoo
KeyBanc Maintains Overweight Rating on GoodRx (GDRX)
GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the 11 Best US Stocks to Invest in Under $5. On May 14, KeyBanc Capital Markets reiterated an 'Overweight' rating on GoodRx Holdings, Inc. (NASDAQ:GDRX) with a price target of $6. KeyBanc's analyst, Scott Schoenhaus, highlighted the current position of GoodRx Holdings, Inc. (NASDAQ:GDRX) within the challenging retail pharmacy industry. The analyst noted that the company is making strategic moves to navigate challenges, including the company's direct contracting strategy and its response to events like the recent Rite Aid bankruptcy. A pharmacist assisting elderly customers with their GoodRX codes at a local pharmacy. GoodRx Holdings, Inc. (NASDAQ:GDRX) is focusing on new opportunities that involve various players in the pharmacy ecosystem, including manufacturers, retailers, pharmacy benefit managers (PBMs), and consumers. While the re-acceleration of Monthly Active Consumers (MACs) might be delayed until next year, GoodRx Holdings, Inc. (NASDAQ:GDRX) has the potential to increase revenue per MAC through these direct contracting relationships. Schoenhaus also expressed confidence in CEO Wendy Barnes and her team's ability to carry out a profitable growth plan, which could lead to higher estimates for 2025. GoodRx Holdings, Inc. (NASDAQ:GDRX) is an American company that is known for its digital healthcare platform that connects consumers, healthcare professionals, payers, PBMs, pharma manufacturers, and retail pharmacies to make medications more accessible. While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-06-2025
- Business
- Yahoo
GoodRx (GDRX) Launches a New Subscription Service for Erectile Dysfunction Treatment
GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, GoodRx Holdings, Inc. (NASDAQ:GDRX) announced launching a new subscription service focused on erectile dysfunction (ED) treatment. The new service aims to innovate access to ED care by addressing common barriers such as high costs, social stigma, long wait times, and inconvenience. The key features of GoodRx Holdings, Inc.'s (NASDAQ:GDRX) new subscription service include an All-in-One Solution through which customers can book virtual consultations, get access to FDA-approved medicines, and also get discreet home deliveries. The subscription starts as low as $18 per month, with the final cost depending on the prescribed medication. We recognize that many men delay or entirely avoid treatment for ED due to stigma, costs, and the inconvenience of traditional healthcare pathways,' said Katelyn Pelak, VP and Head of Product at GoodRx Holdings, Inc. (NASDAQ:GDRX). A pharmacist assisting elderly customers with their GoodRX codes at a local pharmacy. Moreover, the company also released its latest study on ED, revealing nearly 1 in 3 men in the United States report difficulties with erections, but fewer than 14% use any treatment, largely due to insurance coverage gaps and social stigma. GoodRx Holdings, Inc. (NASDAQ:GDRX) is a leading US healthcare company that helps consumers save money on prescription medications by providing free access to drug price comparisons, digital coupons, and discounts at over 70,000 pharmacies nationwide. The company operates through a mobile app and website where users can get medications, access telemedicine services to consult doctors online and receive prescriptions without insurance. It is one of the best small-cap growth stocks to buy according to analysts. While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-06-2025
- Business
- Yahoo
GoodRx (GDRX) Launches a New Subscription Service for Erectile Dysfunction Treatment
GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, GoodRx Holdings, Inc. (NASDAQ:GDRX) announced launching a new subscription service focused on erectile dysfunction (ED) treatment. The new service aims to innovate access to ED care by addressing common barriers such as high costs, social stigma, long wait times, and inconvenience. The key features of GoodRx Holdings, Inc.'s (NASDAQ:GDRX) new subscription service include an All-in-One Solution through which customers can book virtual consultations, get access to FDA-approved medicines, and also get discreet home deliveries. The subscription starts as low as $18 per month, with the final cost depending on the prescribed medication. We recognize that many men delay or entirely avoid treatment for ED due to stigma, costs, and the inconvenience of traditional healthcare pathways,' said Katelyn Pelak, VP and Head of Product at GoodRx Holdings, Inc. (NASDAQ:GDRX). A pharmacist assisting elderly customers with their GoodRX codes at a local pharmacy. Moreover, the company also released its latest study on ED, revealing nearly 1 in 3 men in the United States report difficulties with erections, but fewer than 14% use any treatment, largely due to insurance coverage gaps and social stigma. GoodRx Holdings, Inc. (NASDAQ:GDRX) is a leading US healthcare company that helps consumers save money on prescription medications by providing free access to drug price comparisons, digital coupons, and discounts at over 70,000 pharmacies nationwide. The company operates through a mobile app and website where users can get medications, access telemedicine services to consult doctors online and receive prescriptions without insurance. It is one of the best small-cap growth stocks to buy according to analysts. While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
